Denovo Biopharma

Closed portfolio snapshot

According to ClinicalTrials.gov-derived indexes, Denovo Biopharma sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials none currently recruiting 8 completed top decile by trial count

Denovo Biopharma: 10 sponsored US clinical trials, none currently recruiting.

Denovo Biopharma sponsors 10 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 8 completed. 5 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Schizophrenic Disorders, with 1 trials.

Top-decile sponsor footprint

Denovo Biopharma ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 39/100

8 of 10 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (80.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

10 total, page 1 of 1

COMPLETED Phase 2

A Biomarker-Guided, Randomized, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With TRD

NCT05113771
COMPLETED Phase 3

A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1

NCT03776071
COMPLETED Phase 3

Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™

NCT03263026
COMPLETED Phase 1

A Study Measuring Effect of LY2140023 (Pomaglumetad Methionil) on Electrocardiographs in Participants With Schizophrenia

NCT01606436
COMPLETED Phase 3

A Physical Dependence Study in Schizophrenia

NCT01452919
COMPLETED Phase 1

A Study of Safety and Tolerability in Subjects With Schizophrenia

NCT01354353
TERMINATED Phase 3

A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia Patients

NCT01328093
TERMINATED Phase 3

A Study of LY2140023 in Patients With Schizophrenia

NCT01307800
COMPLETED Phase 2

A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms

NCT01052103
COMPLETED Phase 2

A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients

NCT00845026

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 3
Phase 3 5

Therapeutic Areas

Schizophrenic Disorders 1
Treatment-Resistant Depression 1
Glioblastoma 1

How the Denovo Biopharma archive is shaped

10 indexed studies, none listed as recruiting (0% open); 8 completed (80%).

Phase mix: 5 late (III/IV) vs 5 early (I/II) (balanced across stages).

Top condition: Schizophrenic Disorders (1 trial), 2 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Denovo Biopharma: archived-pipeline peers nationwide

Peers matched on 10 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Denovo Biopharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Denovo BiopharmaAdamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAgouron Pharmaceuticals10xBio22nd Century Group23andMe3-C Institute for Social Development
Denovo Biopharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Denovo Biopharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Denovo Biopharma page

10 registered trials is a research-attention snapshot, not an endorsement of Denovo Biopharma or any single study.

  • None of Denovo Biopharma's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Schizophrenic Disorders is the condition Denovo Biopharma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Schizophrenic Disorders trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Denovo Biopharma pipeline card: 10 registered trials from official public datasets.Report a data error.